KalVista’s Novel DME Approach Moves To Clinical Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s KalVista believes it is pioneering the use of kallikrein inhibitors for diabetic macular edema, including orally active derivatives, as it moves its lead compound into U.S. clinical trials.
You may also be interested in...
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Genentech Says Lucentis DME Product Will Ship Shortly
FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.
U.K. Ophthalmology Spin-Out Raises £8m For DME Programs
SV Life Sciences and Novo AS support spin-out KalVista with £8m to advance preclinical DME programs.